<DOC>
	<DOCNO>NCT00922792</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety pharmacokinetics ( effect body investigated drug ) long act activate recombinant human factor VII ( LA-rFVIIa ) patient haemophilia .</brief_summary>
	<brief_title>Safety Mode Action Single Dose Multiple Doses Long Acting Activated Recombinant Human Factor VII Patients With Haemophilia A B</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Haemophilia A B Bodyweight max 100 kg Body Mass Index ( BMI ) max 30 kg/m2 Adequate venous access Known suspect allergy trial product ( ) relate product ( include NovoSevenÂ® ) The receipt investigational product within 30 day prior enrolment trial Receipt Immune Tolerance Induction ( ITI ) within last 1 month prior participation trial The receipt haemostatic treatment control bleed episode within last 5 day prior administration trial product Receipt FVIII FIX replacement therapy within 48 hour prior trial product administration Known pseudo tumour Congenital acquire coagulation disorder haemophilia A B Any major and/or orthopaedic surgery within one month prior trial start Advanced atherosclerotic disease ( defined know history ischemic heart disease , ischemic stroke , etc . ) Clinical sign renal dysfunction Use platelet inhibitor , include NSAIDs , one week prior administration trial drug Use nonprescribed opiate substance</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>